Drägerwerk AG & Co. KGaA (DRW8) - Cash Flow Conversion Efficiency

Latest as of September 2025: 0.050x

Based on the latest financial reports, Drägerwerk AG & Co. KGaA (DRW8) has a cash flow conversion efficiency ratio of 0.050x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€74.80 Million ≈ $87.45 Million USD) by net assets (€1.51 Billion ≈ $1.76 Billion USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.

Drägerwerk AG & Co. KGaA - Cash Flow Conversion Efficiency Trend (2005–2024)

This chart illustrates how Drägerwerk AG & Co. KGaA's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read total liabilities of Drägerwerk AG & Co. KGaA for a breakdown of total debt and financial obligations.

Drägerwerk AG & Co. KGaA Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Drägerwerk AG & Co. KGaA ranked by their cash flow conversion efficiency.

Company Cash Flow Conversion Efficiency
VITZROCELL Co.Ltd
KQ:082920
0.016x
Guangzhou KingTeller Technology Co Ltd
SHE:002177
0.006x
Global Top E Commerce Co Ltd
SHE:002640
-0.466x
Shenzhen Sunxing Light Alloys
SHG:603978
-0.074x
Prima Andalan Mandiri Tbk PT
JK:MCOL
0.113x
STEVANATO GROUP SPA O.N.
F:87N
0.063x
Zhejiang Shengyang Science
SHG:603703
0.010x
Shanxi Zhendong Pharmaceutical
SHE:300158
-0.055x

Annual Cash Flow Conversion Efficiency for Drägerwerk AG & Co. KGaA (2005–2024)

The table below shows the annual cash flow conversion efficiency of Drägerwerk AG & Co. KGaA from 2005 to 2024. For the full company profile with market capitalisation and key ratios, see DRW8 stock market capitalisation.

Year Net Assets Operating Cash Flow Cash Flow Conversion Efficiency Change
2024-12-31 €1.54 Billion
≈ $1.80 Billion
€167.31 Million
≈ $195.60 Million
0.109x -19.11%
2023-12-31 €1.41 Billion
≈ $1.65 Billion
€189.68 Million
≈ $221.75 Million
0.135x +223.13%
2022-12-31 €1.32 Billion
≈ $1.54 Billion
€-144.23 Million
≈ $-168.62 Million
-0.109x -135.80%
2021-12-31 €1.26 Billion
≈ $1.47 Billion
€384.89 Million
≈ $449.97 Million
0.305x -31.37%
2020-12-31 €1.03 Billion
≈ $1.21 Billion
€459.98 Million
≈ $537.76 Million
0.445x +191.27%
2019-12-31 €1.08 Billion
≈ $1.26 Billion
€164.42 Million
≈ $192.22 Million
0.153x +3936.11%
2018-12-31 €1.08 Billion
≈ $1.26 Billion
€4.09 Million
≈ $4.78 Million
0.004x -97.18%
2017-12-31 €1.07 Billion
≈ $1.25 Billion
€143.34 Million
≈ $167.57 Million
0.134x -31.07%
2016-12-31 €1.00 Billion
≈ $1.17 Billion
€195.32 Million
≈ $228.35 Million
0.195x +361.89%
2015-12-31 €945.93 Million
≈ $1.11 Billion
€39.86 Million
≈ $46.60 Million
0.042x -79.90%
2014-12-31 €896.61 Million
≈ $1.05 Billion
€187.98 Million
≈ $219.77 Million
0.210x +150.33%
2013-12-31 €815.97 Million
≈ $953.95 Million
€68.34 Million
≈ $79.90 Million
0.084x -65.54%
2012-12-31 €727.20 Million
≈ $850.17 Million
€176.75 Million
≈ $206.64 Million
0.243x +10.90%
2011-12-31 €729.62 Million
≈ $853.00 Million
€159.91 Million
≈ $186.95 Million
0.219x -36.34%
2010-12-31 €636.56 Million
≈ $744.21 Million
€219.14 Million
≈ $256.20 Million
0.344x -29.92%
2009-12-31 €393.82 Million
≈ $460.42 Million
€193.45 Million
≈ $226.17 Million
0.491x +160.88%
2008-12-31 €517.64 Million
≈ $605.18 Million
€97.47 Million
≈ $113.95 Million
0.188x -39.66%
2007-12-31 €505.49 Million
≈ $590.97 Million
€157.75 Million
≈ $184.42 Million
0.312x +88.90%
2006-12-31 €539.99 Million
≈ $631.31 Million
€89.21 Million
≈ $104.29 Million
0.165x +41.12%
2005-12-31 €257.68 Million
≈ $301.25 Million
€30.16 Million
≈ $35.27 Million
0.117x --

About Drägerwerk AG & Co. KGaA

XETRA:DRW8 Germany Medical Devices
Market Cap
$831.47 Million
€711.20 Million EUR
Market Cap Rank
#9959 Global
#1189 in Germany
Share Price
€70.00
Change (1 day)
+1.16%
52-Week Range
€49.30 - €77.40
All Time High
€77.40
About

Drägerwerk AG & Co. KGaA operates as a medical and safety technology company worldwide. It develops, produces, and markets system solutions, devices, and services for the medical division, including emergency medicine, perioperative care, intensive care, and perinatal medicine. The company also develops, produces, and markets products, system solutions, and services for personal protection, gas m… Read more